Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2015-06-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.04955-14PMID 26100706PMCID PMC4649205
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance

  2015cited by this paper
• The revival of fosfomycin.

  2011cited by this paper
• Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.

  2010cited by this paper
• Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

  2008cited by this paper
• Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.

  2007cited by this paper
• Performance standards for antimicrobial susceptibility testing

  2001cited by this paper
• Fosfomycin Tromethamine A Review of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Efficacy as a Single-Dose Oral Treatment for Acute Uncomplicated Lower Urinary Tract Infections

  1997cited by this paper
• MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli

  1995cited by this paper
• Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model

  1990cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically

  1990cited by this paper
• THE MECHANISM OF ACTION OF FOSFOMYCIN (PHOSPHONOMYCIN)

  1974cited by this paper
• Phosphonomycin, a New Antibiotic Produced by Strains of Streptomyces

  1969cited by this paper

• Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections?

  2025cites this paper
• Evaluation of the safety profile and intrapulmonary pharmacokinetics of intravenous fosfomycin in healthy adults

  2025cites this paper
• Population Pharmacokinetics of a Novel Oral Fosfomycin Prophylactic Scheme in the Plasma and Prostate of Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia

  2025influential citation
• Enhanced efficacy of sequential administration of fosfomycin and linezolid against methicillin-resistant Staphylococcus aureus

  2025cites this paper
• Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections.

  2024cites this paper
• Optimized fosfomycin regimens for treating carbapenem‐resistant Acinetobacter baumannii in critically ill patients with varying degrees of renal function

  2024cites this paper
• Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature.

  2024cites this paper
• The Impact of Fosfomycin on Gram Negative Infections: A Comprehensive Review

  2024influential citation
• Emergence and Mechanism of Resistance of Tulathromycin Against Mycoplasma hyopneumoniae in a PK/PD Model and the Fitness Costs of 23S rRNA Mutants

  2022cites this paper
• Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model

  2022cites this paper
• Investigations on In Vivo Pharmacokinetic/Pharmacodynamic Determinants of Fosfomycin in Murine Thigh and Kidney Infection Models

  2022cites this paper
• Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections

  2022cites this paper
• Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics

  2021cites this paper
• Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance

  2021cites this paper
• Population Pharmacokinetics and Monte Carlo Simulation for Dosage Optimization of Fosfomycin in the Treatment of Osteoarticular Infections in Patients without Renal Dysfunction

  2021cites this paper
• The pharmacodynamics of fosfomycin against Staphylococcus aureus studied in an in vitro model of infection.

  2020cites this paper
• Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection

  2020cites this paper
• Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers

  2020cites this paper
• In Vitro Pharmacodynamics of Fosfomycin against Carbapenem-Resistant Enterobacter cloacae and Klebsiella aerogenes

  2020cites this paper
• Urinary Pharmacokinetic and Pharmacodynamic Profiles of Fosfomycin against Extended-Spectrum β-Lactamase-Producing Escherichia coli with Canine Ex Vivo Modeling: A Pilot Study

  2020cites this paper
• Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model

  2020cites this paper
• Pharmacokinetic-pharmacodynamic integration and resistance of tiamulin against Mycoplasma hyopneumoniae in an in vitro dynamic model.

  2020cites this paper
• New perspectives for reassessing fosfomycin: applicability in current clinical practice

  2019cites this paper
• Current approach to fosfomycin: From bench to bedside

  2019cites this paper
• Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?

  2019cites this paper
• ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections.

  2019cites this paper
• Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients.

  2019cites this paper
• Deciphering pharmacokinetics and pharmacodynamics of fosfomycin

  2019cites this paper
• What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review

  2019cites this paper
• Current approach to fosfomycin: From bench to bedside.

  2019cites this paper
• Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide

  2019cites this paper
• Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model

  2018cites this paper
• Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam – epidemiology, laboratory detection and treatment implications

  2018cites this paper
• Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.

  2018cites this paper
• Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model

  2018cites this paper
• Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model

  2018cites this paper
• Individualising Therapy to Minimize Bacterial Multidrug Resistance

  2018cites this paper
• Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.

  2018cites this paper
• PK/PD-Based Prediction of “Anti-Mutant” Antibiotic Exposures Using In Vitro Dynamic Models

  2018cites this paper
• Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae

  2018cites this paper
• Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model

  2018cites this paper
• Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae.

  2017cites this paper
• Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers

  2017cites this paper
• Pre‐clinical in vitro infection models

  2017cites this paper
• The Antibiotic Future

  2017cites this paper
• Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae

  2017cites this paper
• Fosfomycin: Mechanism and Resistance.

  2017cites this paper
• Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae

  2017cites this paper
• Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model.

  2017influential citation
• Molecular insights into fosfomycin resistance in Escherichia coli

  2017cites this paper
• In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa

  2017cites this paper
• Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model

  2016cites this paper
• Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model

  2016cites this paper
• Is a New Standard Needed for Diffusion Methods for In Vitro Susceptibility Testing of Fosfomycin against Pseudomonas aeruginosa?

  2015cites this paper
• In vitro susceptibility testing of fosfomycin in Pseudomonas 1 aeruginosa , do we need a new standard for diffusion methods ?

  2015cites this paper